CTSI June 2018 Newsletter

Three Decades of Research Culminates in FDA Drug Approval

Share on FacebookTweet about this on TwitterShare on LinkedInEmail this to someone

Indiana CTSI e-newsletter content from June 2018

By IU School of Medicine and CTSI Staff Reports:
Indiana CTSI-supported research led by two Indiana University School of Medicine faculty members has culminated in U.S. Food and Drug Administration approval of a new drug for patients with an uncommon, painful and deforming bone disease.

Michael Econs and Kenneth White

IU School of Medicine researchers Michael Econs and Kenneth White (Photo courtesy of Indiana University)

The drug, burosumab, treats X-linked hypophosphatemia, or XLH. It is being brought to market by Ultragenyx Pharmaceutical Inc. in collaboration with Kyowa Hakko Kirin Co., Ltd. and its European subsidiary, Kyowa Kirin International PLC, under the brand name Crysvita.
XLH is a phosphate-wasting disease that causes rickets and osteomalacia, or softening of the bones. It is typically inherited and affects more than 12,000 patients in the United States and one out of every 20,000 people worldwide. Patients are typically diagnosed as children and have bowed legs, short stature, and experience bone pain and dental abscesses.

The first ever human dose of burosumab was administered by an Indiana CTSI Clinical Research Center (CRC) nurse on January 27, 2009. CRC staff conducted study procedures for all clinic study visits associated with the Phase I – III studies (eight studies total), which included 46 patients (aged 1 year to 70 years) and 822 total study visits, and the CRC continues to support this important work with an upcoming Phase IV study.

Read more.

Pawsitive results

CTSI-supported researchers at Purdue recently published a new study that shows how veterans with PTSD may benefit physiologically from using service dogs.

Read more.

Growing talent

Central Indiana area high school students are exploring careers in science this summer by working in the labs of research mentors at CTSI partner institutions.

Read more.

Meet Anna Roberts

Get to know the Indiana CTSI’s new Data Navigator, who serves as a resource for researchers looking to harness data expertise available through the Regenstrief Institute.

Read more.

Bench to bedside

Early research supported by the CTSI has helped lead to the launch of a first-in-human clinical trial at IU School of Medicine that aims to treat an aggressive type of breast cancer.

Read more.

Tune in

CTSI Director Anantha Shekhar will discuss the recent Indiana CTSI 3.0 grant renewal and what it means for the health of our state this weekend on Inside Indiana Business TV.

Read more.

CTSI IN THE NEWS

Want to more CTSI updates? Follow us on TwitterLinkedIn and Facebook

UPCOMING EVENTS

View all upcoming events.

By |2019-04-10T12:21:42-04:00June 3rd, 2018|Comments Off on CTSI June 2018 Newsletter

About the Author:

Kimberly Haddad

Get Involved with Indiana CTSI